Lead Product(s) : CTX-101
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Ferndale Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Crescita Reports Topline Results from Two Pivotal Clinical Studies
Details : Both studies of CTX-101 met the primary endpoint for psoriasis, CTX-101 is a topical formulation utilizing a corticosteroid in combination with our patented MMPE technology
Product Name : CTX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : CTX-101
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Ferndale Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable